HRP20220065T1 - Kristal derivata pirido[3,4-d]pirimidina ili njegov solvat - Google Patents
Kristal derivata pirido[3,4-d]pirimidina ili njegov solvat Download PDFInfo
- Publication number
- HRP20220065T1 HRP20220065T1 HRP20220065TT HRP20220065T HRP20220065T1 HR P20220065 T1 HRP20220065 T1 HR P20220065T1 HR P20220065T T HRP20220065T T HR P20220065TT HR P20220065 T HRP20220065 T HR P20220065T HR P20220065 T1 HRP20220065 T1 HR P20220065T1
- Authority
- HR
- Croatia
- Prior art keywords
- ppm
- peaks
- spectrum
- crystal according
- recognizable
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title claims 17
- 239000012453 solvate Substances 0.000 title claims 2
- 159000000016 pyrido[3,4-d]pyrimidines Chemical class 0.000 title 1
- 238000001228 spectrum Methods 0.000 claims 9
- 239000007787 solid Substances 0.000 claims 8
- 238000010521 absorption reaction Methods 0.000 claims 7
- 238000000862 absorption spectrum Methods 0.000 claims 7
- 238000000113 differential scanning calorimetry Methods 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 238000000634 powder X-ray diffraction Methods 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 5
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 claims 4
- 238000002204 nitrogen-15 nuclear magnetic resonance spectrum Methods 0.000 claims 4
- ASPVIYXYPZWJTE-CYBMUJFWSA-N 1-[6-[[6-[(1R)-1-hydroxyethyl]-8-(propan-2-ylamino)pyrido[3,4-d]pyrimidin-2-yl]amino]pyridin-3-yl]piperazin-2-one Chemical compound O[C@H](C)C1=CC2=C(N=C(N=C2)NC2=CC=C(C=N2)N2C(CNCC2)=O)C(=N1)NC(C)C ASPVIYXYPZWJTE-CYBMUJFWSA-N 0.000 claims 2
- MYYRRIVAHMMVRI-CQSZACIVSA-N 6-[(1R)-1-methoxyethyl]-2-N-(6-piperazin-1-ylpyridazin-3-yl)-8-N-propan-2-ylpyrido[3,4-d]pyrimidine-2,8-diamine Chemical compound C(C)(C)NC1=NC(=CC2=C1N=C(N=C2)NC=1N=NC(=CC=1)N1CCNCC1)[C@@H](C)OC MYYRRIVAHMMVRI-CQSZACIVSA-N 0.000 claims 2
- HBNFVZUWDSWOOH-MRXNPFEDSA-N 6-[(1R)-1-methoxyethyl]-2-N-[5-(piperazin-1-ylmethyl)pyridin-2-yl]-8-N-propan-2-ylpyrido[3,4-d]pyrimidine-2,8-diamine Chemical compound C(C)(C)NC1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)CN1CCNCC1)[C@@H](C)OC HBNFVZUWDSWOOH-MRXNPFEDSA-N 0.000 claims 2
- 238000007707 calorimetry Methods 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 208000013557 cerebral hemisphere cancer Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 201000008860 cerebrum cancer Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Walking Sticks, Umbrellas, And Fans (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (16)
1. Kristal spoja predstavljenog formulom (I):
[image]
naznačen time što R1 predstavlja vodikov atom ili skupinu C1-3 alkil, R2 predstavlja vodikov atom ili okso skupinu, L predstavlja jednostruku vezu ili skupinu C1-3 alkilen, i X predstavlja CH ili N;
ili njegov solvat,
pri čemu je spoj predstavljen formulom (I) odabran iz skupine koju čine:
1-(6-((6-((1R)-1-hidroksietil)-8-(izopropilamino)pirido[3,4-d]pirimidin-2-il)amino)-3-piridil)piperazin-2-on;
1-(6-((6-((1R)-1-metoksietil)-8-(izopropilamino)pirido[3,4-d]pirimidin-2-il)amino)-3-piridazil)piperazin; i
(R)-N8-izopropil-6-(1-metoksietil)-N2-(5-(piperazin-1-ilmetil)piridin-2-il)pirido[3,4-d]pirimidin-2,8-diamin.
2. Kristal prema patentnom zahtjevu 1, naznačen time što je spoj 1-(6-((6-((1R)-1-hidroksietil)-8-(izopropilamino)pirido[3,4-d]pirimidin-2-il)amino)-3-piridil)piperazin-2-on.
3. Kristal prema patentnom zahtjevu 2, naznačen time što pokazuje vrhove pri kutovima difrakcije 2θ = 6.3°, 6.6°, 11.6°, 16.9° i 20.0° na spektru difrakcije rendgenskih zraka na prahu, te poželjno dalje pokazuje jedno ili više od sljedećeg (i) do (iv):
(i) ekstrapoliranu početnu temperaturu za endotermni vrh od 277°C prema diferencijalnoj pretražnoj kalorimetriji;
(ii) prepoznatljive apsorpcijske vrhove s valnim brojevima od 703 cm-1, 896 cm-1 i 3418 cm-1 na infracrvenom apsorpcijskom spektru primjenom KBr postupka;
(iii) prepoznatljive vrhove na 136.0 ppm, 111.2 ppm, 105.1 ppm, 101.8 ppm, 52.7 ppm, 49.6 ppm, 42.9 ppm, 23.8 ppm i 18.5 ppm na čvrstom 13C NMR spektru;
(iv) prepoznatljive vrhove na 248.6 ppm, 245.7 ppm, 229.2 ppm, 214.5 ppm, 174.3 ppm, 86.5 ppm, 54.7 ppm i -12.4 ppm na čvrstom 15N NMR spektru.
4. Kristal prema patentnom zahtjevu 2, naznačen time što pokazuje vrhove pri kutovima difrakcije 2θ = 5.3°, 7.3°, 10.3°, 15.1° i 17.4° na spektru difrakcije rendgenskih zraka na prahu, te poželjno dalje pokazuje jedno ili više od sljedećeg (i) do (iv):
(i) ekstrapoliranu početnu temperaturu za endotermni vrh od 277°C prema diferencijalnoj pretražnoj kalorimetriji;
(ii) prepoznatljive apsorpcijske vrhove s valnim brojevima od 874 cm-1, 1330 cm-1 i 3314 cm-1 na infracrvenom apsorpcijskom spektru primjenom KBr postupka;
(iii) prepoznatljive vrhove na 154.7 ppm, 138.8 ppm, 133.6 ppm, 113.2 ppm, 101.6 ppm, 100.4 ppm, 67.4 ppm, 51.8 ppm, 26.6 ppm i 23.3 ppm na čvrstom 13C NMR spektru;
(iv) prepoznatljive vrhove na 243.6 ppm, 86.7 ppm, 56.7 ppm i -12.4 ppm na čvrstom 15N NMR spektru.
5. Kristal prema patentnom zahtjevu 2, naznačen time što pokazuje vrhove pri kutovima difrakcije 2θ = 5.3°, 6.0°, 6.7°, 10.4° i 20.8° na spektru difrakcije rendgenskih zraka na prahu, te poželjno dalje pokazuje ekstrapoliranu početnu temperaturu za endotermni vrh od 271°C prema diferencijalnoj pretražnoj kalorimetriji.
6. Kristal prema patentnom zahtjevu 2, naznačen time što pokazuje vrhove pri kutovima difrakcije 2θ = 6.0 °, 10.0°, 13.7°, 20.3° i 23.0° na spektru difrakcije rendgenskih zraka na prahu te poželjno dalje pokazuje jedno ili više od sljedećeg (i) i (ii):
(i) ekstrapoliranu početnu temperaturu za endotermni vrh od 100°C i 278°C prema diferencijalnoj pretražnoj kalorimetriji;
(ii) prepoznatljive apsorpcijske vrhove s valnim brojevima od 840 cm-1, 904 cm-1, 955 cm-1, 1490 cm-1 i 3281 cm-1 na infracrvenom apsorpcijskom spektru primjenom KBr postupka.
7. Kristal prema patentnom zahtjevu 2, naznačen time što pokazuje vrhove pri kutovima difrakcije 2θ = 5.2°, 7.2°, 9.5°, 14.5°, 16.5°, 20.9°, 25.0° i 27.9° na spektru difrakcije rendgenskih zraka na prahu, te poželjno dalje pokazuje jedno ili više od sljedećeg (i) i (ii):
(i) ekstrapoliranu početnu temperaturu za endotermni vrh od 272°C prema diferencijalnoj pretražnoj kalorimetriji;
(ii) prepoznatljive apsorpcijske vrhove s valnim brojevima od 1081 cm-1 i 1260 cm-1 na infracrvenom apsorpcijskom spektru primjenom KBr postupka.
8. Kristal prema patentnom zahtjevu 1, naznačen time što je spoj 1-(6-((6-((1R)-1-metoksietil)-8-(izopropilamino)pirido[3,4-d]pirimidin-2-il)amino)-3-piridazil)piperazin.
9. Kristal prema patentnom zahtjevu 8, naznačen time što pokazuje vrhove pri kutovima difrakcije 2θ = 5.2°, 7.6°, 8.4°, 10.5°, 15.2°, 16.9°, 20.1°, 21.0°, 23.3° i 26.6° na spektru difrakcije rendgenskih zraka na prahu, te poželjno dalje pokazuje jedno ili više od sljedećeg (i) do (iv):
(i) ekstrapoliranu početnu temperaturu za endotermni vrh od 225°C prema diferencijalnoj pretražnoj kalorimetriji;
(ii) prepoznatljive apsorpcijske vrhove s valnim brojevima od 1369 cm-1, 1424 cm-1, 1508 cm-1, 1545 cm-1 i 1566 cm-1 na infracrvenom apsorpcijskom spektru primjenom KBr postupka;
(iii) prepoznatljive vrhove na 163.4 ppm, 157.6 ppm, 155.5 ppm, 117.8 ppm, 82.2 ppm, 56.1 ppm i 42.3 ppm na čvrstom 13C NMR spektru;
(iv) prepoznatljive vrhove na 311.7 ppm, 232.4 ppm, 168.5 ppm, 79.5 ppm, 53.3 ppm, 32.9 ppm i - 4.3 ppm na čvrstom 15N NMR spektru.
10. Kristal prema patentnom zahtjevu 8, naznačen time što pokazuje vrhove pri kutovima difrakcije 2θ = 5.2°, 6.6°, 8.1°, 15.2°, 15.9°, 16.2°, 18.8°, 20.5°, 20.8° i 21.7°, na spektru difrakcije rendgenskih zraka na prahu, te poželjno dalje pokazuje ekstrapoliranu početnu temperaturu za endotermni vrh od 221°C prema diferencijalnoj pretražnoj kalorimetriji.
11. Kristal prema patentnom zahtjevu 8, naznačen time što pokazuje vrhove pri kutovima difrakcije 2θ =5.2°, 7.6°, 8.4°, 10.0°, 10.5°, 11.9°, 15.2°, 17.0°, 20.9°i 21.2°, na spektru difrakcije rendgenskih zraka na prahu, te poželjno dalje pokazuje jedno ili više od sljedećeg (i) i (ii):
(i) ekstrapoliranu početnu temperaturu za endotermni vrh od 223°C prema diferencijalnoj pretražnoj kalorimetriji;
(ii) prepoznatljive apsorpcijske vrhove s valnim brojevima od 1369 cm-1, 1424 cm-1, 1507cm-1, 1546cm-1 i 1566 cm-1 na infracrvenom apsorpcijskom spektru primjenom KBr postupka.
12. Kristal prema patentnom zahtjevu 1, naznačen time što je spoj (R)-N8-izopropil-6-(1-metoksietil)-N2-(5-(piperazin-1-ilmetil)piridin-2-il)pirido[3,4-d]pirimidin-2,8-diamin.
13. Kristal prema patentnom zahtjevu 12, naznačen time što pokazuje vrhove pri kutovima difrakcije 2θ = 4.8°, 7.6°, 8.2°, 9.7°, 15.3°, 16.6°, 19.1°, 19.8°, 22.4°i 26.2° na spektru difrakcije rendgenskih zraka na prahu, i koji po mogućnosti pokazuje jedno ili više od sljedećeg (i) do (iv):
(i) ekstrapoliranu početnu temperaturu za endotermni vrh od 182°C prema diferencijalnoj pretražnoj kalorimetriji;
(ii) prepoznatljive apsorpcijske vrhove s valnim brojevima od 1115 cm-1,1446 cm-1, 1508 cm-1, 1560 cm-1 i 1601 cm-1 na infracrvenom apsorpcijskom spektru primjenom KBr postupka;
(iii) prepoznatljive vrhove na 161.3 ppm, 150.8 ppm, 138.9 ppm, 128.1 ppm, 109.8 ppm, 82.7 ppm, 47.6 ppm, 42.5 ppm, 41.5 ppm, 24.5 ppm i 21.7 ppm na čvrstom 13C NMR spektru;
(iv) prepoznatljive vrhove na 242.8 ppm, 233.8 ppm, 219.0 ppm, 171.7 ppm, 86.9 ppm, 54.9 ppm, 11.3 ppm i -5.5 ppm na čvrstom 15N NMR spektru.
14. Farmaceutski pripravak naznačen time što sadrži kristal prema bilo kojem od patentnih zahtjeva 1 do 13 i farmaceutski prihvatljiv nosač.
15. Farmaceutski pripravak za upotrebu kao inhibitor CDK4/6, naznačen time što sadrži kristal prema bilo kojem od patentnih zahtjeva 1 do 13 kao aktivni sastojak.
16. Kristal prema bilo kojem od patentnih zahtjeva 1 do 13 naznačen time što je za upotrebu za profilaksu ili liječenje reumatoidnog artritisa, arterioskleroze, plućne fibroze, cerebralnog infarkta i/ili raka.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016229973 | 2016-11-28 | ||
| EP17873876.1A EP3546456B1 (en) | 2016-11-28 | 2017-11-27 | Crystal of pyrido[3, 4-d]pyrimidine derivative or solvate thereof |
| PCT/JP2017/042437 WO2018097295A1 (ja) | 2016-11-28 | 2017-11-27 | ピリド［３，４－ｄ］ピリミジン誘導体又はその溶媒和物の結晶 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220065T1 true HRP20220065T1 (hr) | 2022-04-15 |
Family
ID=62196036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220065TT HRP20220065T1 (hr) | 2016-11-28 | 2017-11-27 | Kristal derivata pirido[3,4-d]pirimidina ili njegov solvat |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US11261182B2 (hr) |
| EP (1) | EP3546456B1 (hr) |
| JP (2) | JP6745905B2 (hr) |
| KR (1) | KR102352637B1 (hr) |
| CN (1) | CN109996800B (hr) |
| AU (1) | AU2017364805B2 (hr) |
| CA (1) | CA3041854A1 (hr) |
| CL (3) | CL2019001420A1 (hr) |
| CO (1) | CO2019005513A2 (hr) |
| CY (1) | CY1125045T1 (hr) |
| DK (1) | DK3546456T3 (hr) |
| EC (1) | ECSP19037197A (hr) |
| ES (1) | ES2905437T3 (hr) |
| HR (1) | HRP20220065T1 (hr) |
| HU (1) | HUE057706T2 (hr) |
| IL (1) | IL266313B2 (hr) |
| LT (1) | LT3546456T (hr) |
| MA (1) | MA45887B1 (hr) |
| MX (1) | MX382362B (hr) |
| MY (1) | MY199852A (hr) |
| PE (2) | PE20191133A1 (hr) |
| PH (1) | PH12019500905A1 (hr) |
| PL (1) | PL3546456T3 (hr) |
| PT (1) | PT3546456T (hr) |
| RS (1) | RS63004B1 (hr) |
| SI (1) | SI3546456T1 (hr) |
| TW (1) | TWI755452B (hr) |
| UA (1) | UA124273C2 (hr) |
| WO (1) | WO2018097295A1 (hr) |
| ZA (1) | ZA201902828B (hr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025070601A1 (ja) * | 2023-09-27 | 2025-04-03 | 帝人ファーマ株式会社 | 関節リウマチ治療薬 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MEP46108A (hr) | 2002-01-22 | 2011-02-10 | Warner Lambert Co | 2-(piridin-2-ilamino)-pirido (2,3-d) pirimidin-7-oni |
| ATE433967T1 (de) * | 2003-01-17 | 2009-07-15 | Warner Lambert Co | 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation |
| DE602004017474D1 (de) | 2003-07-11 | 2008-12-11 | Warner Lambert Co | Isethionat salz eines selektiven cdk4 inhibitors |
| GEP20135785B (en) | 2008-08-22 | 2013-03-11 | Novartis Ag | Pyrrolopyrimidine compounds as cdk inhibitors |
| GB201216017D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
| CN105682661B (zh) * | 2013-08-23 | 2020-03-27 | 润新生物公司 | 某些化学实体、组合物和方法 |
| GB201403536D0 (en) * | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
| DK3150599T3 (en) * | 2014-05-29 | 2019-01-14 | Taiho Pharmaceutical Co Ltd | HIS UNKNOWN TETRAHYDROPYRIDOPYRIMIDE COMPOUND OR SALT THEREOF |
| US9643965B2 (en) | 2014-09-17 | 2017-05-09 | Celgene Quantical Research, Inc. | Histone demethylase inhibitors |
| US10124004B2 (en) * | 2015-05-29 | 2018-11-13 | Teijin Pharma Limited | Pyrido[3,4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof |
-
2017
- 2017-11-27 PL PL17873876T patent/PL3546456T3/pl unknown
- 2017-11-27 CA CA3041854A patent/CA3041854A1/en active Pending
- 2017-11-27 MY MYPI2019002381A patent/MY199852A/en unknown
- 2017-11-27 HU HUE17873876A patent/HUE057706T2/hu unknown
- 2017-11-27 ES ES17873876T patent/ES2905437T3/es active Active
- 2017-11-27 US US16/463,501 patent/US11261182B2/en active Active
- 2017-11-27 SI SI201731055T patent/SI3546456T1/sl unknown
- 2017-11-27 CN CN201780073120.6A patent/CN109996800B/zh active Active
- 2017-11-27 LT LTEPPCT/JP2017/042437T patent/LT3546456T/lt unknown
- 2017-11-27 EP EP17873876.1A patent/EP3546456B1/en active Active
- 2017-11-27 KR KR1020197015052A patent/KR102352637B1/ko active Active
- 2017-11-27 TW TW106141156A patent/TWI755452B/zh active
- 2017-11-27 HR HRP20220065TT patent/HRP20220065T1/hr unknown
- 2017-11-27 IL IL266313A patent/IL266313B2/en unknown
- 2017-11-27 AU AU2017364805A patent/AU2017364805B2/en active Active
- 2017-11-27 JP JP2018553004A patent/JP6745905B2/ja active Active
- 2017-11-27 PT PT178738761T patent/PT3546456T/pt unknown
- 2017-11-27 MX MX2019005717A patent/MX382362B/es unknown
- 2017-11-27 RS RS20220187A patent/RS63004B1/sr unknown
- 2017-11-27 PE PE2019001068A patent/PE20191133A1/es unknown
- 2017-11-27 WO PCT/JP2017/042437 patent/WO2018097295A1/ja active IP Right Grant
- 2017-11-27 MA MA45887A patent/MA45887B1/fr unknown
- 2017-11-27 UA UAA201905840A patent/UA124273C2/uk unknown
- 2017-11-27 DK DK17873876.1T patent/DK3546456T3/da active
- 2017-11-27 PE PE2023003166A patent/PE20250397A1/es unknown
-
2019
- 2019-04-24 PH PH12019500905A patent/PH12019500905A1/en unknown
- 2019-05-06 ZA ZA2019/02828A patent/ZA201902828B/en unknown
- 2019-05-24 CL CL2019001420A patent/CL2019001420A1/es unknown
- 2019-05-27 CO CONC2019/0005513A patent/CO2019005513A2/es unknown
- 2019-05-27 EC ECSENADI201937197A patent/ECSP19037197A/es unknown
-
2020
- 2020-04-06 JP JP2020068663A patent/JP7149980B2/ja active Active
-
2021
- 2021-06-02 CL CL2021001447A patent/CL2021001447A1/es unknown
- 2021-06-02 CL CL2021001448A patent/CL2021001448A1/es unknown
-
2022
- 2022-03-04 CY CY20221100183T patent/CY1125045T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110234652B (zh) | 苯并咪唑衍生物及其制备方法和用途 | |
| AU2011274192B2 (en) | Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof | |
| NL1029016C2 (nl) | Tetrahydronafthyridinederivaten. | |
| US20210053984A1 (en) | Mk2 inhibitors and uses thereof | |
| AU2018256459A1 (en) | Indole AHR inhibitors and uses thereof | |
| JP2025037892A (ja) | ピロロピリミジンｉｔｋ阻害剤 | |
| AU2012299080B2 (en) | Pyrimidine PDE10 inhibitors | |
| AU2007227203B2 (en) | 6,7,8, 9 -tetrahydro- 5H- pyrimido [4, 5-d] azepin-4-yl] -amine derivatives as modulators of TRPVL for the treatment of pain | |
| CA3172203A1 (en) | Process, compositions, and crystalline forms of substituted pyridinone-pyridinyl compounds | |
| CA3034010A1 (en) | Amino-pyrrolopyrimidinone compounds and methods of use thereof | |
| US11981665B2 (en) | Substituted pyrimidines, pharmaceutical compositions and therapeutic methods thereof | |
| CA2933755A1 (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| IL191432A (en) | History of pyrimidine, medicinal preparations containing them, process of preparation and use of pharmaceutical preparations | |
| JP2020525512A (ja) | 癌および他の疾患を処置するためのＡＴＦ４阻害剤としての２−（４−クロロフェノキシ）−Ｎ−（（１−（２−（４−クロロフェノキシ）エチンアゼチジン（ｅｔｈｙｎａｚｅｔｉｄｉｎ）−３−イル）メチル）アセトアミド誘導体および関連化合物 | |
| WO2015180642A1 (en) | Certain protein kinase inhibitors | |
| WO2021211741A1 (en) | Substituted pyridines for the treatment of inflammatory diseases | |
| AU2017364720A1 (en) | Novel oxoisoquinoline derivative | |
| US20140315909A1 (en) | 3,5-(Un)substituted-1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H- pyrrolo[2,3-b]pyrazine dual ITK and JAK3 Kinase Inhibitors | |
| HRP20220065T1 (hr) | Kristal derivata pirido[3,4-d]pirimidina ili njegov solvat | |
| CA3132348A1 (en) | Degraders of fibroblast growth factor receptor 2 (fgfr2) | |
| JP2020121989A5 (hr) | ||
| HK40009806B (zh) | 苯並咪唑衍生物及其製備方法和用途 | |
| HK40009806A (en) | Benzimidazole derivatives, preparation methods and uses theirof | |
| WO2019125838A1 (en) | Purine inhibitors of human phosphatidylinositol 3-kinase delta | |
| Dabaeva et al. | Synthesis and Neurotropic Activity of New Condensed Pyrido [3′, 2′: 4, 5] furo [3, 2-d]-pyrimidine Derivatives |